Biofrontera (B8F.DE XETRA) rises to €6.80 intraday 03 Feb 2026: heavy volume may set trend

Intraday action shows B8F.DE stock trading at €6.80 on XETRA on 03 Feb 2026 on unusually heavy volume. The move follows a wide intraday range from €0.30 to €6.80, with reported volume at 45,797 shares versus an average volume of 605. Traders are reacting to liquidity and recent company developments while the stock trades well above its 50-day average of €6.53 and below its 200-day average of €9.19. We summarise the drivers, valuation, technicals, and what the Meyka AI model projects for the next 12 months.

B8F.DE stock: intraday price and volume

Biofrontera AG (B8F.DE) opened at €0.37 and hit a day high of €6.80 on XETRA. Volume surged to 45,797 shares, giving a relative volume of 75.70. The previous close was €0.32, so the intraday change measured €6.48. The company has 3,038,430 shares outstanding and a market cap of €20,673,478.00.

The intraday range and volume point to a concentrated block trade or news-driven flow. Average daily volume is 605.00, so this session is a clear high-volume mover worth watching for follow-through.

Drivers and B8F.DE stock news

No new public earnings report is listed for today, but market participants reference product sales mix and partnership updates. Biofrontera markets dermatology products such as Ameluz and BF-RhodoLED across the United States, Europe, and Israel. The company reported last EPS at -0.21 per share, which helps explain valuation sensitivity.

Sector flows in Healthcare are muted, with drug manufacturers trading cautiously. High intraday volume in B8F.DE stock likely reflects short-covering and speculative trading rather than broad sector momentum.

Financials and valuation of Biofrontera AG

Key ratios show a small-cap specialty drug maker with mixed metrics. EPS is -0.21, and reported PE is -32.40. Price to Sales is 0.64, and Price to Book is 21.73. Enterprise Value to Sales is 0.58, and EV/EBITDA is 3.36.

Liquidity and balance-sheet metrics look stable. Cash per share is €0.05, current ratio 1.76, and debt to equity 0.06. Gross profit margin is 78.67%, while net margin remains negative at -1.14%, reflecting a small net loss on slim revenues.

B8F.DE stock: technical outlook and Meyka AI grade

Technically, B8F.DE stock trades above the 50-day average €6.53 and below the 200-day average €9.19. Day low was €0.30 and day high €6.80, suggesting extreme intra-session volatility. Watch the €6.50–€7.00 band for support and €9.20 for medium-term resistance.

Meyka AI rates B8F.DE with a score of 58.59 out of 100 — Grade C+ (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not investment advice.

Meyka AI’s forecast and analyst price targets

Meyka AI’s forecast model projects a 12-month base target of €10.00, implying an upside of 46.92% from the current €6.80. The model also outlines a conservative scenario near €5.00 and an optimistic scenario near €18.00.

Forecasts are model-based projections and not guarantees. They reflect recent volatility, limited free-float, and small market cap dynamics. Investors should treat these targets as scenario markers rather than certainties.

Risks, catalysts and trading strategy

Key risks include continued volatility, thin liquidity outside heavy-volume sessions, and negative trailing EPS. The stock’s small float can amplify moves and widen spreads. Regulatory or clinical results could trigger outsized reactions.

Catalysts to watch include product sales updates, partnership announcements, and any formal filings. For traders, tight stop placement is prudent. For longer-term investors, evaluate fundamentals, research spend (24.33% of revenue), and cash runway before committing capital.

Final Thoughts

B8F.DE stock is a high-volume mover on 03 Feb 2026, trading at €6.80 on XETRA with 45,797 shares changing hands. The session shows heavy speculative activity and a wide intraday range from €0.30 to €6.80. Financially, the company posts EPS -0.21, price-to-sales 0.64, and a market cap near €20.67 million. Meyka AI rates B8F.DE with a 58.59/100 score (Grade C+, HOLD) and projects a 12-month base target of €10.00, an implied upside of 46.92%. Forecasts are model-based projections and not guarantees. Traders should watch follow-through volume and the €6.50–€7.00 support band. Long-term investors must weigh operational cash, product momentum, and regulatory news before adjusting positions. Meyka AI provides this update as an AI-powered market analysis platform to help frame the move and next steps.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.